ALFA Filings
Every announcement, straight from the exchange
Every OneSource Specialty Pharma regulatory approval announcement on NSE and BSE, newest first, each with its own page.
Time
3 announcements with these filters
OneSource Specialty Pharma received Karnataka government approval for its Unit II expansion project. The facility expansion enhances manufacturing capacities to service global partners and support growth.
OneSource Specialty Pharma's partner, Orbicular, received Health Canada approval for a generic version of Ozempic (semaglutide). This marks the second generic semaglutide approval in Canada, the world's second-largest market for the drug. OneSource will support commercial supply from its FDA-approved Bengaluru facility, strengthening its global CDMO position in complex injectables.
OneSource Specialty Pharma's partner, Dr. Reddy's Laboratories, received Health Canada approval for its generic Semaglutide injection (Ozempic® generic). OneSource will serve as the CDMO partner providing scale-up and commercial manufacturing from its US-FDA approved Bengaluru facility. This regulatory milestone strengthens the partnership and leverages OneSource's specialty manufacturing capabilities.